

Casciano Anthony
Form 3
April 05, 2019

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

<p>1. Name and Address of Reporting Person *</p> <p>Â Casciano Anthony</p> <p>(Last) (First) (Middle)</p> <p>C/O AMAG PHARMACEUTICALS, INC.,Â 1100 WINTER STREET</p> <p>(Street)</p> <p>WALTHAM,Â MAÂ 02451</p> <p>(City) (State) (Zip)</p>	<p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>04/04/2019</p>	<p>3. Issuer Name and Ticker or Trading Symbol</p> <p>AMAG PHARMACEUTICALS INC. [AMAG]</p>	<p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p><input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) Chief Commercial Officer</p>	<p>5. If Amendment, Date Original Filed(Month/Day/Year)</p>	<p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p><input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person</p>
---	---	--	--	---	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	45,852 ⁽¹⁾	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	--	---	---	--

Edgar Filing: Casciano Anthony - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	Â (2)	09/06/2026	Common Stock	20,000	\$ 24.18	D	Â
Stock Option (Right to Buy)	Â (3)	02/23/2027	Common Stock	8,000	\$ 23.75	D	Â
Stock Option (Right to Buy)	Â (4)	03/02/2028	Common Stock	18,000	\$ 21	D	Â
Stock Option (Right to Buy)	Â (5)	10/11/2028	Common Stock	8,000	\$ 21.6	D	Â
Stock Option (Right to Buy)	Â (6)	02/25/2029	Common Stock	16,156	\$ 15.57	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Casciano Anthony C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM, MA 02451	Â	Â	Â Chief Commercial Officer	Â

Signatures

Nancy R. Smith,
attorney-in-fact

04/05/2019

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Includes 43,244 shares of unvested restricted stock options ("RSUs"), each of which represents a contingent right to receive one share of common stock of AMAG Pharmaceuticals, Inc. (the "Issuer").

(2) Grant of stock options pursuant to the Issuer's Third Amended and Restated 2007 Equity Incentive Plan (as amended, the "Plan"). The initial option award provided for the vesting of four equal annual installments with the final vesting date to occur on September 6, 2020.

Grant of stock options pursuant to the Plan. The initial option award provided for vesting over four years after the grant date as follows:

(3) (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter with the final vesting date to occur on February 23, 2021.

Grant of stock options pursuant to the Plan. The initial option award provided for vesting over four years after the grant date as follows:

(4) (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter with the final vesting date to occur on March 2, 2022.

Grant of stock options pursuant to the Plan. The initial option award provided for vesting over four years after the September 4, 2018 (the

(5) "Vesting Date") date as follows: (i) 25% on the first anniversary of the Vesting Date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter with the final vesting date to occur on September 4, 2022.

(6) Grant of stock options pursuant to the Plan. The initial option award provided for vesting over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years

Edgar Filing: Casciano Anthony - Form 3

thereafter with the final vesting date to occur on February 25, 2023.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.